收购事件概述 - 瑞士制药公司诺华同意以120亿美元收购Avidity Biosciences [1] 交易主体 - 收购方为瑞士制药公司诺华 [1] - 被收购方为生物科技公司Avidity Biosciences [1] 交易金额 - 交易总金额为120亿美元 [1]

Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipelineExpected to unlock multi-billion-dollar opportunities with planned product launches before 2030 Raises expected 2024-2029 sales CAGR for Novartis from +5% to +6%, an ...

Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipelineExpected to unlock multi-billion-dollar opportunities with planned product launches before 2030 Raises expected 2024-2029 sales CAGR for Novartis from +5% to +6%, an ...

Signage for Novartis AG at a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported, citing a person familiar with the matter.A deal could be announced as early as Sunday, the report said.Novartis and Avidity didn't immediately respond to CNBC's requests for comment.Avidity specializes in developing an innovative class ...

Swiss pharmaceutical major Novartis AG is “nearing” a deal to acquire biotechnology company Avidity Biosciences Inc., according to a Bloomberg report citing sources.Novartis is in discussions to buy Avidity for more than $70 a share, the source said. The deal could be announced as early as on October 26 (US time), if there are no “last minute snags”, the report added.Spokespeople for both Avidity and Novartis did not immediately respond to queries on the matter. The report came outside of usual business hou ...

并购交易 - 瑞士制药公司诺华接近收购美国生物技术公司Avidity Biosciences [1] - 交易价格预计超过每股70美元 [1]

诺华公司潜在收购 - 瑞士制药巨头诺华公司据报接近达成收购罕见病生物技术公司Avidity Biosciences的交易 [2] - 此次潜在收购符合公司加强其在罕见遗传病等高增长治疗领域产品组合的战略 [2] - 收购目标公司专注于开发用于神经肌肉适应症的抗体寡核苷酸偶联物，市场估值约为46亿美元 [2] 道达尔能源液化天然气项目 - 道达尔能源公司已告知莫桑比克，其大型液化天然气项目成本自2021年停工以来增加了45亿美元 [3] - 该项目总投资额约为200亿美元，公司近期解除了因安全担忧而实施的“不可抗力”状态 [3] - 项目全面重启取决于莫桑比克部长理事会批准包含更新预算和时间表的开发计划附录 [3] 英国与土耳其战略合作 - 英国首相计划访问土耳其，旨在加强两国战略伙伴关系并讨论地区和国际发展 [6] - 会谈议程关键项目包括最终敲定一项价值数十亿美元的欧洲战斗机“台风”交易 [6] - 土耳其计划采购多达40架欧洲战斗机“台风” [6]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novartis is making one of the largest dealmaking gambles in its history, agreeing on Sunday to spend billions of dollars to acquire biotechnology company Avidity Biosciences, which is working on RNA medicines for rare neuromuscular conditions. Per deal terms, Novartis is paying $72 per share to acquire Avidity. The offer values Avidity at $12 billion and repre ...

Novartis (NYSE:NVS) is in advanced discussions to acquire Avidity Biosciences (NASDAQ:RNA), Bloomberg News reported Sunday, citing a person with knowledge of the negotiations. The Swiss pharmaceutical company is said to be preparing an offer exceeding $70 per share for the U.S.-based ...

Novartis AG (NYSE:NVS) is one of the stocks that was recently put under the microscope by Jim Cramer. During the lightning round, a caller asked if they should buy, sell, or hold the stock. In response, Cramer said, “Oh, come on, Vas [CEO Vasant (Vas) Narasimhan] is a winner… I’m a buyer of Novartis.” lucarista/Shutterstock.com Novartis AG (NYSE:NVS) develops, manufactures, and markets prescription medicines across cardiovascular, immunology, neuroscience, oncology, and hematology areas. Loomis Sayles s ...